Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer

2013 ◽  
Vol 13 (4) ◽  
pp. 239-246.e1 ◽  
Author(s):  
Andrew D. Seidman ◽  
Alison K. Conlin ◽  
Ariadne Bach ◽  
Mary Ellen Moynahan ◽  
Diana Lake ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
First Line ◽  
Randomized Phase Ii ◽  
Line Chemotherapy

Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival

2012 ◽  
Vol 12 (5) ◽  
pp. 313-321 ◽  
Author(s):  
William J. Gradishar ◽  
Dimitry Krasnojon ◽  
Sergey Cheporov ◽  
Anatoly N. Makhson ◽  
Georgiy M. Manikhas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
Final Analysis ◽  
First Line ◽  
Line Chemotherapy

Phase II Trial of Weekly Docetaxel/Gemcitabine as First-Line Chemotherapy in Patients with Locally Recurrent or Metastatic Breast Cancer

2006 ◽  
Vol 6 (6) ◽  
pp. 505-510 ◽  
Author(s):  
Joyce A. O'Shaughnessy ◽  
Robert Pluenneke ◽  
Jack Sternberg ◽  
Pankaj Khandelwal ◽  
Des Ilegbodu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Breast ◽  
First Line ◽  
Weekly Docetaxel ◽  
Locally Recurrent ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document